EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 92 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide on Cancer Pain Management Now Available Also in French FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment MOST POPULAR Enhertu May Be Preferred Therapy for Some Metastatic Breast Cancers October 19, 2021 Manageable Safety and Promising Activity of Neoadjuvant Pembrolizumab plus Vibostolimab, Pembrolizumab... January 21, 2025 EMA Recommends Granting a Marketing Authorisation for Vorasidenib August 13, 2025 Young Woman Considers Service Dog A Crucial Ally In Her Battle... July 20, 2020 Load more HOT NEWS What the Reignited Cancer Moonshot Initiative Means for People With Cancer Tratamiento agnóstico contra el cáncer: perspectiva de un experto Jiffy Lube Surprises Volunteer Who Drives Cancer Patients To Treatment With... Be a Holiday Helper!
